“What if it causes anaphylaxis?”
“What if it makes me sick?”
“What if it doesn’t work?”
“Once I take it I can’t undo it.”
For most people, starting a new prescription is routine – pick it up, get generic instructions from the pharmacist, take it, then report back to your doctor in a few weeks. For many people living with chronic illness, that same act can trigger a spiral of intrusive thoughts, severe procrastination, and genuine dread. It isn’t dramatics, and it isn’t a lack of trust in medicine. It’s the accumulated weight of a body that has reacted unpredictably before, sometimes severely, sometimes in ways that took months for anyone to connect back to a pill, or the experience of being fine taking it one day and having a completely different experience the next.
I recently posted a video documenting exactly this: the anxiety, the racing thoughts, and the physical toll of working up the nerve to take a new medication. The response was immediate and enormous. Comments poured in from people describing the same private ritual of fear, the mental rehearsal of worst-case scenarios, the need to have someone else in the house before swallowing a single pill, the tears that come while trying to negotiate your way into just taking the dang medication.
Other people described being terrified of new medications after a lifetime of allergic reactions and unpredictable side effects; some said they still ask a parent or partner to stay overnight, even as adults, just in case something goes wrong. Others explained a habit of halving a new pill before ever taking a full dose, just to test the waters. People with chronic illnesses – colitis, clotting disorders, narcolepsy, MCAS – chimed in with their own versions of the same fear: worrying that a medication meant to help will instead cause harm. Several described sobbing through a first dose. Most said they felt less alone after seeing a part of being chronically ill that tends to go unspoken, brought to light without shame.
Why EDS Bodies Specifically Can React Differently
Ehlers-Danlos syndrome is a group of connective tissue disorders, and the most common form, hypermobile EDS (hEDS), along with hypermobile spectrum disorder (HSD), is strongly linked to a cluster of inflammatory and immune conditions. Among the most significant is mast cell activation syndrome (MCAS), a disorder in which mast cells – immune cells that release histamine, tryptase, and other inflammatory chemicals – fire off in inappropriate or exaggerated ways.
A 2022 review in Immunologic Research examined this overlap in detail and found that mast cell activation disorders show up disproportionately often in people with hEDS and HSD. The authors point to a plausible mechanism: mast cell mediators like tryptase can interact with connective tissue itself, which may help explain why the two conditions travel together so often. Other research on the same association has found the odds of an MCAS diagnosis are several times higher in people with hEDS than in the general population, and that a notable portion of MCAS patients also carry an hEDS diagnosis. For patients, this makes introducing anything new, including a medication meant to help, feel genuinely riskier.
When the Reaction Doesn’t Match the Drug
One of the most disorienting aspects of unexplained medication reactions is that they often don’t seem to make sense to patients or their doctors. Someone can be prescribed a medication with a well-established safety profile and still end up with hives, flushing, gastrointestinal distress, or a mysterious decline in symptoms that seems to have no clinical correlation.
Research on medication intolerance in MCAS patients offers an explanation that rarely comes up in a typical doctor’s appointment. A 2019 paper in The American Journal of the Medical Sciences describes how MCAS makes patients unusually sensitive not just to active drug ingredients but to the “inactive” ones: the dyes, fillers, preservatives, and alcohols used to bind, color, or stabilize a pill or injection. The authors document cases where patients reacted not to a medication itself, but to a dye in the capsule, an alcohol-based preservative in an injectable solution, or a filler switched between manufacturers when a prescription was refilled. In several cases, patients tolerated one formulation of a drug for years and then reacted badly the moment their pharmacy switched suppliers, with nothing about the active ingredient having changed at all.
That explains a pattern many in the chronic illness community know well: being told a reaction “shouldn’t” be happening, because on paper, the drug is safe and those side effects weren’t reported in the clinical trials. The fear is a rational response to a body that has reacted to something that didn’t come with that warning label.
The Power of Showing the Unseen
What came through most clearly in the comments on that video wasn’t despair, but recognition. Person after person described feeling less alone after watching someone else document the same anxious spiral they had , at one time, quietly carried. Several said they’d never seen anyone show the “ugly” parts of medication anxiety, the crying, the panic, the need for a support person nearby, and that seeing it normalized made them feel both more validated and more willing to try again themselves.
For the chronic illness community, the fear of a new medication is rarely about the medication alone. It’s about a body that has learned, sometimes painfully, that it doesn’t always play by the rules everyone else does. Naming that fear publicly, and having growing bodies of research connecting chronic illness, EDS, MCAS, and unpredictable drug reactions, tells patients they were never overreacting in the first place (even though their mast cell might be).
By Tayler Goectau,
clinical research coordinator,
disability advocate
@distaaybled
August, 2026
